Aflibercept for untreated wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have not had any previous treatment for wet AMD in the study eye
- You have active wet AMD with fluid in the retina, confirmed by imaging
- Your vision in the study eye is between 20/32 and 20/320 (moderate to severe vision loss)
- You are willing to use effective contraception if you or your partner could become pregnant
- You do not have uncontrolled high blood pressure or other serious eye conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
This study tests a new higher-dose version of an eye injection called aflibercept (Eylea) for people with a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this treatment is effective, long-lasting, and safe, and it may help improve or preserve your vision.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.